Gene therapy for Parkinson's disease: A step closer?

The Lancet

Volumn 383, Issue 9923, 2014, Pages 1107-1109

  Jon Stoessl, A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; GLUTAMATE DECARBOXYLASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LENTIVIRUS VECTOR; LEVODOPA; LEVODOPA F 18; METHYLPHENIDATE; NEURTURIN; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; DOPAMINE RECEPTOR STIMULATING AGENT; RACLOPRIDE;

BRAIN DEPTH STIMULATION; DAILY LIFE ACTIVITY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; INFUSION; MOOD; NEUROIMAGING; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL NOISE RATIO; SUBTHALAMIC NUCLEUS; THINKING; UNIFIED PARKINSON DISEASE RATING SCALE; VIRAL GENE THERAPY; GENE THERAPY;

ANTIPARKINSON AGENTS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INFECTIOUS ANEMIA VIRUS, EQUINE; MALE; PARKINSON DISEASE; TRANSFECTION;

EID: 84897068891     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62108-X     Document Type: Note

References (12)

1. Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 718-79.
2. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589-95.
3. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399-406.
4. Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol 2012; 11: 429-42.
5. Barker RA, Barrett J, Mason SL, Bjorklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol 2013; 12: 84-91.
6. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011; 10: 309-19.
7. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 1164-72.
8. PalfiS, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014; published online Jan 10. http://dx.doi.org/10.1016/S0140-6736(13)61939-X.
9. Mittermeyer G, Christine CW, Rosenbluth KH, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012; 23: 377-81.
10. Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Antonini A. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. Funct Neurol 2012; 27: 147-54.
11. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3: 309-16.
12. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology 2007; 69: 1701-11.